On 13 January 2025, Shanghai Henlius announced that it has entered a product licence and supply agreement with Abbott under which Abbott is granted exclusive or semi-exclusive rights to the commercialisation of four biosimilars and one innovative biologic. The commercialisation rights cover 69 emerging markets in Asia, Latin America, Middle East and Africa.
The identities of the products licensed under the agreement have not been disclosed, but the first products are expected to be launched in 2027, with some still subject to clinical trials and regulatory approval.
Henlius and Abbott have previously entered collaborations for the commercialisation of oncology biosimilars, including Hanlikang® (biosimilar rituximab) and Hanquyou® (biosimilar trastuzumab) in Brazil.